The majority of analyst ratings for Marinus Pharma are bullish or somewhat bullish, indicating a positive outlook for the stock. However, the average 12-month price target has decreased by 6.85%, which may suggest a slightly less optimistic view compared to the previous average. This could lead to a short-term increase in the stock price, but with a potential slowdown in the longer term.